598 related articles for article (PubMed ID: 11373411)
1. Lenercept (p55 tumor necrosis factor receptor fusion protein) in severe sepsis and early septic shock: a randomized, double-blind, placebo-controlled, multicenter phase III trial with 1,342 patients.
Abraham E; Laterre PF; Garbino J; Pingleton S; Butler T; Dugernier T; Margolis B; Kudsk K; Zimmerli W; Anderson P; Reynaert M; Lew D; Lesslauer W; Passe S; Cooper P; Burdeska A; Modi M; Leighton A; Salgo M; Van der Auwera P;
Crit Care Med; 2001 Mar; 29(3):503-10. PubMed ID: 11373411
[TBL] [Abstract][Full Text] [Related]
2. p55 Tumor necrosis factor receptor fusion protein in the treatment of patients with severe sepsis and septic shock. A randomized controlled multicenter trial. Ro 45-2081 Study Group.
Abraham E; Glauser MP; Butler T; Garbino J; Gelmont D; Laterre PF; Kudsk K; Bruining HA; Otto C; Tobin E; Zwingelstein C; Lesslauer W; Leighton A
JAMA; 1997 May; 277(19):1531-8. PubMed ID: 9153367
[TBL] [Abstract][Full Text] [Related]
3. Anti-inflammatory response after infusion of p55 soluble tumor necrosis factor receptor fusion protein for severe sepsis.
Butty VL; Roux-Lombard P; Garbino J; Dayer JM; Ricou B;
Eur Cytokine Netw; 2003; 14(1):15-9. PubMed ID: 12799209
[TBL] [Abstract][Full Text] [Related]
4. Impact of immunomodulating therapy on morbidity in patients with severe sepsis.
Pittet D; Harbarth S; Suter PM; Reinhart K; Leighton A; Barker C; Macdonald F; Abraham E
Am J Respir Crit Care Med; 1999 Sep; 160(3):852-7. PubMed ID: 10471608
[TBL] [Abstract][Full Text] [Related]
5. TNF neutralization in MS: results of a randomized, placebo-controlled multicenter study. The Lenercept Multiple Sclerosis Study Group and The University of British Columbia MS/MRI Analysis Group.
Neurology; 1999 Aug; 53(3):457-65. PubMed ID: 10449104
[TBL] [Abstract][Full Text] [Related]
6. Selenium in Intensive Care (SIC): results of a prospective randomized, placebo-controlled, multiple-center study in patients with severe systemic inflammatory response syndrome, sepsis, and septic shock.
Angstwurm MW; Engelmann L; Zimmermann T; Lehmann C; Spes CH; Abel P; Strauss R; Meier-Hellmann A; Insel R; Radke J; Schüttler J; Gärtner R
Crit Care Med; 2007 Jan; 35(1):118-26. PubMed ID: 17095947
[TBL] [Abstract][Full Text] [Related]
7. Intravenous human recombinant tumor necrosis factor receptor p55-Fc IgG1 fusion protein, Ro 45-2081 (lenercept): results of a dose-finding study in rheumatoid arthritis.
Furst DE; Weisman M; Paulus HE; Bulpitt K; Weinblatt M; Polisson R; Zaug M; Kneer J; Van der Auwera P; Stevens RM
J Rheumatol; 2003 Oct; 30(10):2123-6. PubMed ID: 14528504
[TBL] [Abstract][Full Text] [Related]
8. Importance of underlying mechanism and genotype on outcome of sepsis trials.
McIntyre L; Walley KR
Crit Care Med; 2001 Mar; 29(3):677-9. PubMed ID: 11373447
[No Abstract] [Full Text] [Related]
9. Efficacy and safety of monoclonal antibody to human tumor necrosis factor alpha in patients with sepsis syndrome. A randomized, controlled, double-blind, multicenter clinical trial. TNF-alpha MAb Sepsis Study Group.
Abraham E; Wunderink R; Silverman H; Perl TM; Nasraway S; Levy H; Bone R; Wenzel RP; Balk R; Allred R
JAMA; 1995 Mar 22-29; 273(12):934-41. PubMed ID: 7884952
[TBL] [Abstract][Full Text] [Related]
10. Evaluating the efficacy and safety of two doses of the polyclonal anti-tumor necrosis factor-α fragment antibody AZD9773 in adult patients with severe sepsis and/or septic shock: randomized, double-blind, placebo-controlled phase IIb study*.
Bernard GR; Francois B; Mira JP; Vincent JL; Dellinger RP; Russell JA; Larosa SP; Laterre PF; Levy MM; Dankner W; Schmitt N; Lindemann J; Wittebole X
Crit Care Med; 2014 Mar; 42(3):504-11. PubMed ID: 24335445
[TBL] [Abstract][Full Text] [Related]
11. Efficacy and safety of the monoclonal anti-tumor necrosis factor antibody F(ab')2 fragment afelimomab in patients with severe sepsis and elevated interleukin-6 levels.
Panacek EA; Marshall JC; Albertson TE; Johnson DH; Johnson S; MacArthur RD; Miller M; Barchuk WT; Fischkoff S; Kaul M; Teoh L; Van Meter L; Daum L; Lemeshow S; Hicklin G; Doig C;
Crit Care Med; 2004 Nov; 32(11):2173-82. PubMed ID: 15640628
[TBL] [Abstract][Full Text] [Related]
12. Plasma granulocyte colony-stimulating factor and granulocyte-macrophage colony-stimulating factor levels in critical illness including sepsis and septic shock: relation to disease severity, multiple organ dysfunction, and mortality.
Presneill JJ; Waring PM; Layton JE; Maher DW; Cebon J; Harley NS; Wilson JW; Cade JF
Crit Care Med; 2000 Jul; 28(7):2344-54. PubMed ID: 10921563
[TBL] [Abstract][Full Text] [Related]
13. Intravenous human recombinant tumor necrosis factor receptor p55-Fc IgG1 fusion protein Ro 45-2081 (lenercept): a double blind, placebo controlled dose-finding study in rheumatoid arthritis.
Rau R; Sander O; van Riel P; van de Putte L; Hasler F; Zaug M; Kneer J; van der Auwera P; Stevens RM;
J Rheumatol; 2003 Apr; 30(4):680-90. PubMed ID: 12672184
[TBL] [Abstract][Full Text] [Related]
14. Treatment of septic shock with the tumor necrosis factor receptor:Fc fusion protein. The Soluble TNF Receptor Sepsis Study Group.
Fisher CJ; Agosti JM; Opal SM; Lowry SF; Balk RA; Sadoff JC; Abraham E; Schein RM; Benjamin E
N Engl J Med; 1996 Jun; 334(26):1697-702. PubMed ID: 8637514
[TBL] [Abstract][Full Text] [Related]
15. Confirmatory interleukin-1 receptor antagonist trial in severe sepsis: a phase III, randomized, double-blind, placebo-controlled, multicenter trial. The Interleukin-1 Receptor Antagonist Sepsis Investigator Group.
Opal SM; Fisher CJ; Dhainaut JF; Vincent JL; Brase R; Lowry SF; Sadoff JC; Slotman GJ; Levy H; Balk RA; Shelly MP; Pribble JP; LaBrecque JF; Lookabaugh J; Donovan H; Dubin H; Baughman R; Norman J; DeMaria E; Matzel K; Abraham E; Seneff M
Crit Care Med; 1997 Jul; 25(7):1115-24. PubMed ID: 9233735
[TBL] [Abstract][Full Text] [Related]
16. Inappropriate initial antimicrobial therapy and its effect on survival in a clinical trial of immunomodulating therapy for severe sepsis.
Harbarth S; Garbino J; Pugin J; Romand JA; Lew D; Pittet D
Am J Med; 2003 Nov; 115(7):529-35. PubMed ID: 14599631
[TBL] [Abstract][Full Text] [Related]
17. Effect of pentoxifylline in severe sepsis: results of a randomized, double-blind, placebo-controlled study.
Staubach KH; Schröder J; Stüber F; Gehrke K; Traumann E; Zabel P
Arch Surg; 1998 Jan; 133(1):94-100. PubMed ID: 9438767
[TBL] [Abstract][Full Text] [Related]
18. INTERSEPT: an international, multicenter, placebo-controlled trial of monoclonal antibody to human tumor necrosis factor-alpha in patients with sepsis. International Sepsis Trial Study Group.
Cohen J; Carlet J
Crit Care Med; 1996 Sep; 24(9):1431-40. PubMed ID: 8797612
[TBL] [Abstract][Full Text] [Related]
19. Initial evaluation of human recombinant interleukin-1 receptor antagonist in the treatment of sepsis syndrome: a randomized, open-label, placebo-controlled multicenter trial.
Fisher CJ; Slotman GJ; Opal SM; Pribble JP; Bone RC; Emmanuel G; Ng D; Bloedow DC; Catalano MA;
Crit Care Med; 1994 Jan; 22(1):12-21. PubMed ID: 8124953
[TBL] [Abstract][Full Text] [Related]
20. Antithrombin III in patients with severe sepsis. A randomized, placebo-controlled, double-blind multicenter trial plus a meta-analysis on all randomized, placebo-controlled, double-blind trials with antithrombin III in severe sepsis.
Eisele B; Lamy M; Thijs LG; Keinecke HO; Schuster HP; Matthias FR; Fourrier F; Heinrichs H; Delvos U
Intensive Care Med; 1998 Jul; 24(7):663-72. PubMed ID: 9722035
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]